Evidence map›Paper›PMID 34285710›Full record

ArticleJournal of the renin-angiotensin-aldosterone system : JRAAS2021

Angiotensin II Induces Differentiation of Human Neuroblastoma Cells by Increasing MAP2 and ROS Levels.

Bryan Jael Collazo, Dariana Morales-Vázquez, Jaylene Álvarez-Del Valle, Javier E Sierra-Pagan, Juan Carlos Medina, Jarold Méndez-Álvarez, Yamil Gerena

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the renin-angiotensin-aldosterone system : JRAAS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Peptidergic Systems and Neuroblastoma.International journal of molecular sciences · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bryan Jael CollazoDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067.ORCID https://orcid.org/0000-0002-4819-2836
Dariana Morales-VázquezDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067.ORCID https://orcid.org/0000-0002-0686-5246
Jaylene Álvarez-Del ValleDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067.ORCID https://orcid.org/0000-0001-6520-2904
Javier E Sierra-PaganDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067.ORCID https://orcid.org/0000-0002-6155-4336
Juan Carlos MedinaDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067.ORCID https://orcid.org/0000-0002-0689-3140
Jarold Méndez-ÁlvarezDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067.ORCID https://orcid.org/0000-0003-4833-5208
Yamil GerenaDepartment of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico, Medical Sciences Campus, PO Box 365067, San Juan, Puerto Rico 00936-5067.ORCID https://orcid.org/0000-0002-5324-109X
University of Puerto Rico, Medical Sciences Campus · PR

Funding

Upstream Regulation and Downstream effectors of c-MYC in Ovarian CancerU54MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Abiel Roche-Lima · 2017 to 2026
$35.8M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
RIO PIEDRAS MARC U*STAR DEVELOPMENT PROGRAMT34GM007821 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 1985 to 2020
$20.3M
Exosome-mediated soluble insulin receptor secretion correlates with HAND Administrative Supplement HurricanesR01NS099036 · NINDS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI GERENA, YAMIL, WOJNA, VALERIE · 2016 to 2021
$2.6M
NIGMS NIH HHS R25 GM061838NIGMS NIH HHS T34 GM007821NIMHD NIH HHS U54 MD007600NINDS NIH HHS R01 NS099036
6 · The paper itself

Abstract

introductionThe roles of angiotensin II (Ang II) in the brain are still under investigation. In this study, we investigated if Ang II influences differentiation of human neuroblastoma cells with simultaneous activation of NADPH oxidase and reactive oxygen species (ROS). Moreover, we investigated the Ang II receptor type involved during differentiation.

methodsHuman neuroblastoma cells (SH-SY5Y; 5 × 10

results(1) Cell size decreased significantly in Ang II-treated cells; (2) MAP2 and ROS increased significantly in Ang II-treated cells with no changes in viability; (3) MAP2 and ROS decreased significantly in cells incubated with Ang II plus apocynin. (4) A significant decrease in MAP2 was observed in cells exposed to Ang II plus PD123.319 (AT2R blocker).

conclusionOur findings suggest that Ang II influences differentiation of SH-SY5Y by increasing MAP2 through the AT2R. The increase in MAP2 and ROS were also mediated through NADPH oxidase with no cell death.

Indexed as

Angiotensin IINeuroblastomaCell DifferentiationHumansMicrotubule-Associated ProteinsNADPH OxidasesReactive Oxygen SpeciesAngiotensin IIMAP2 protein, humanMicrotubule-Associated ProteinsNADPH OxidasesReactive Oxygen Species

Identifiers

PMID34285710
PMCPMC8265025
OpenAlexW3166989093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.